Hepatitis C virus (genotype 4)-associated mixed cryoglobulinemia vasculitis: Effects of antiviral treatment

Hepatology International

Volumn 6, Issue 3, 2012, Pages 606-612

  El Khayat, Hisham R ^a   Fouad, Yasser M ^b   Ahmad, Ezzat Ali ^c   El Amin, Hussein ^d   Ismael, Faten ^b   Rizk, Amal ^e  

^a THEODOR BILHARZ RESEARCH INSTITUTE   (Egypt)

^b MINIA UNIVERSITY   (Egypt)

^c ALEXANDRIA UNIVERSITY   (Egypt)

^d ASSIUT UNIVERSITY   (Egypt)

^e CAIRO UNIVERSITY   (Egypt)

Author keywords

Cryoglobulinemia; Hepatitis C; Interferon

Indexed keywords

CRYOGLOBULIN; PEGINTERFERON ALPHA2A; PREDNISONE; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; ERADICATION THERAPY; FEMALE; FIBROSIS; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGICAL PARAMETERS; INFECTION CONTROL; MALE; MEDICAL PARAMETERS; MICROBIOLOGICAL PARAMETERS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEINURIA; PURPURA; REMISSION; RISK ASSESSMENT; RISK FACTOR; SJOEGREN SYNDROME; TREATMENT DURATION; TREATMENT RESPONSE; VASCULITIS;

EID: 84865517749     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-011-9303-x     Document Type: Article

References (26)

1. Cacoub P, Poynard T, Ghillani P, for the MULTIVIRC Group, et al. Extrahepatic manifestations of chronic hepatitis C. Arthritis Rheum 1999;42:2204-2212
2. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992;327: 1490-1495
3. Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994;330:751-756
4. Dammacco F, Sansonno D, Han JH, et al. Natural interferon versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 1994;84:3336-3343
5. Tarantino A, Campise M, Banfi G, et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995;47:618-623
6. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982
7. Cacoub P, Saadoun D, Sene D, Limal N, Piette JC. Treatment of hepatitis C virus-related systemic vasculitis. J Rheumatol 2005; 32:2078-2082
8. Saadoun D, Resche-Rigon M, Thibault V, Piette V, Cacoub P. Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum 2006;54(11):3696-3706
9. The French METAVIR, Group CooperativeStudy, Bedossa P. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;20:15-20
10. Musset L, Diemert MC, Taibi F, et al. Characterization of cryoglobulins by immunoblotting. Clin Chem 1992;38:798-802
11. Rustgi VK. The epidemiology of hepatitis C infection in the United States. J Gastroenterol 2007;42:513-521
12. Mazzaro C, Zorat F, Caizzi M, et al. Treatment with peg-interferon a-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol 2005;42:632-638
13. Hauser SC, Pardi DS, Poterucha JJ. Mayo Clinic Gastroenterology and Hepatology Board Review. Mayo Clinic Scientific Press, MN (2006
14. Liang TJ. Shortened therapy for hepatitis C virus genotype 2 or 3. Is less more? N Engl J Med 2007;357:176-178
15. Ali S, Meidinger RR, Kayali Z et al. Outcomes of pegylated interferon and ribavirin therapy for HCV patients with cryoglobulinemia as compared to patients without cryoglobulinemia. Gastroenterology 2007;132:A790
16. Cacoub P, Lidove O, Maisonobe T, et al. Interferon and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2002;46:3317-3326
17. Naarendorp M, Kallemuchikkal U, Nuovo GJ, Gorevic PD. Longterm efficacy of interferon for extra hepatic disease associated with hepatitis C virus infection. J Rheumatol 2001;28:2466-2473
18. Zuckerman E, Keren D, Slobodin G, et al. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon. J Rheumatol 2000;27: 2172-2178
19. Tallarita T, Gagliano M, Corona D, et al. (2009) Successful combination of Rituximab and plasma exchange in the treatment of cryoglobulinemic vasculitis with skin ulcers: a case report. Cases J 2:7859
20. Lamprecht P, Moosig F, Gause A, et al. Immunological and clinical follow up of hepatitis C virus associated cryoglobulinaemic vasculitis. Ann Rheum Dis 2001;60:385-390
21. Alric L, Plaisier E, Thebault S, et al. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis 2004;43:617-623
22. Gota C, Fessler BJ, Calabrese LH, Cooper SM. Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus. J Rheumatol 2005;32:1164-1167
23. Roccatello D, Baldovino S, Rossi D, et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004;19:3054-3061
24. Tallarita T, Gagliano M, Corona D, et al. Successful combination of Rituximab and plasma exchange in the treatment of cryoglobulinemic vasculitis with skin ulcers: a case report. Cases J 2009;2:7859
25. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of Chronic hepatitis C: a randomized trial. Lancet 2001;358:958-965
26. Dammacco F, Tucci FA, Lauletta G, et al. Pegylated interferonalpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: A long-term study. Blood 2010;116(3):343-353